Role for combination therapy in diabetic dyslipidemia (Q38430793)

3 September 2017

1 reference

title

Role for combination therapy in diabetic dyslipidemia (English)

1 reference

3 September 2017

1 reference

Haider J Warraich

1

1 reference

3 September 2017

Nathan D Wong

series ordinal

2

1 reference

3 September 2017

Jamal S Rana

series ordinal

3

1 reference

3 September 2017

1 May 2015

1 reference

Current cardiology reports

3 September 2017

1 reference

3 September 2017

17

1 reference

3 September 2017

5

1 reference

3 September 2017

32

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-015-0589-5

3 September 2017

0 references

cites work

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Diabetes and cardiovascular disease. The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Cardiovascular disease in type 2 diabetes mellitus: current management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Is type 2 diabetes really a coronary heart disease risk equivalent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Dyslipidemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Prevention of Diabetes With Mediterranean Diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Extended-release niacin (nicotinic acid)/laropiprant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0589-5

Cholesterol treatment guidelines update

21 January 2018

1 reference

12 December 2020

U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study

1 reference

12 December 2020

Dyslipidemia of central obesity and insulin resistance.

1 reference

12 December 2020

High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy

1 reference

12 December 2020

Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study

1 reference

12 December 2020

Statins for the primary prevention of cardiovascular disease

1 reference

12 December 2020

Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM

1 reference

12 December 2020

Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis

1 reference

12 December 2020

The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3

1 reference

12 December 2020

10.1007/S11886-015-0589-5

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference